This variant is localized in the ATPase domain of the AFG3L2 clustered in the ATPase domain with other pathogenetic variants causing alteration of OPA1 processing and associated with optic neuropathy, presenting clinical features nearly indistinguishable from OPA1-related DOA [6, 14]. Here, OPA1 is linked to optic nerve disorder.